- Went public, May 2017
- Raised $250M funding round, Mar 2026
- Raised $120M funding round led by Great Point Partners, Jul 2023
About
UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated.
The company has developed RTGel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained-release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option.
UroGen's lead product candidates, UGN-101 (mitomycin urothelial gel, known as MitoGel) and UGN-102 (mitomycin intravesical gel, known as VesiGel), are designed to potentially remove tumors by nonsurgical means and to treat several forms of non-muscle-invasive urothelial cancer, including low-grade upper-tract urothelial carcinoma and bladder cancer, respectively.
In April 2020, the FDA accepted for filing UroGen's new drug application for UGN-101 (mitomycin gel) for the treatment of low-grade upper-tract urothelial cancer. UGN-101 will be the only drug available for this type of cancer.
Funding history · 7 rounds · $522.2M total
Q&A
- What was UroGen Pharma's most recent funding round?
- In March 2026, UroGen Pharma secured $250,000,000 in funding.
- Which investors participated in UroGen Pharma's July 2023 funding round?
- In July 2023, UroGen Pharma raised $120,000,000 from investors including.
- When did UroGen Pharma go public and on which exchange?
- UroGen Pharma became public on NASDAQ in May 2017 through an Initial Public Offering, raising $58,200,000 at a valuation of $155,600,000.
- What was the amount of UroGen Pharma's public offering in June 2024?
- In June 2024, UroGen Pharma conducted a public offering on NASDAQ, raising $107,500,000.
- What is UroGen Pharma's primary focus as a biotech company?
- UroGen Pharma is a biotech company focused on developing novel solutions for specialty cancers and urologic diseases, utilizing its proprietary RTGel sustained-release, hydrogel-based platform technology.
- What is the status of UGN-102, one of UroGen Pharma's lead product candidates?
- In October 2024, the FDA accepted UroGen Pharma's New Drug Application for UGN-102 for bladder cancer treatment. This follows the initiation of a rolling NDA submission in January 2024 and a completed submission in August 2024, seeking approval as the first FDA-approved treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer.
- What was a significant leadership appointment at UroGen Pharma in October 2024?
- In October 2024, UroGen Pharma appointed Chris Degnan as its new Chief Financial Officer.
- What recent patent allowance did UroGen Pharma receive?
- In September 2024, UroGen Pharma received a new U.S. patent allowance for its next-generation mitomycin-based products, expected to provide protection until December 2041.
- What is the current employee count range for UroGen Pharma?
- UroGen Pharma has 201–500 employees.
- What was a key development for UroGen Pharma's JELMYTO® in September 2022?
- In September 2022, the FDA authorized an extension of the in-use period for UroGen Pharma's JELMYTO® Admixture to 96 hours following reconstitution.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | urogen.com |
|---|---|
| linkedin.com/company/11520884 | |
| YouTube | youtube.com/channel/UCfocvR6Si3Awb5beahHHlzg |
Identifiers & details
| Former names | Theracoat, TheraCoat |
|---|---|
| Founded | 2004-4 |
| Employees (exact) | 315 |
| Offices | Princeton |
| Market cap | $1.1B |
| Status reason | Public on NASDAQ on May 2017; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2017-05 | $58.2M | |||
| 2018-01 | $60.0M | |||
| 2019-01 | $150.0M | |||
| 2024-06 | $107.5M |